Assessment of Fecal Markers and Clinical Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Results from PURSUIT-SC Induction
William J. Sandborn(University of San Diego), Paul Rutgeerts(KU Leuven), Dino Tarabar(Military Medical Academy), Peter G. Gibson(University Gastroenterology), Brian G. Feagan(Western University), Colleen Marano(Johnson & Johnson (United States)), Hongyan Zhang(Janssen (United States)), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Walter Reinisch(Medical University of Vienna), Judith Collins(Oregon Health & Science University), Richard Strauß(Hennepin County Medical Center), Jewel Johanns(Johnson & Johnson (United States)), Zbigniew Hebzda(1 Military Clinical Hospital with Outpatient Clinic)
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k